Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth von Yeung, C L, Ngo, V N, Grohar, P J, Arnaldez, F I, Asante, A, Wan, X, Khan, J, Hewitt, S M, Khanna, C, Staudt, L M, Helman, L J

Volltext

Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth von Arnaldez, F. I., Yeung, C. L., Grohar, P. J., Helman, L. J.

Volltext

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma von Ligon, John A, Sundby, R Taylor, Wedekind, Mary F, Arnaldez, Fernanda I, Del Rivero, Jaydira, Wiener, Lori, Srinivasan, Ramaprasad, Spencer, Melissa, Carbonell, Amanda, Lei, Haiyan, Shern, John, Steinberg, Seth M, Figg, William D, Peer, Cody J, Zimmerman, Sara, Moraly, Josquin, Xu, Xia, Fox, Stephen, Chan, King, Barbato, Michael I, Andresson, Thorkell, Taylor, Naomi, Pacak, Karel, Killian, J Keith, Dombi, Eva, Linehan, W Marston, Miettinen, Markku, Piekarz, Richard, Helman, Lee J, Meltzer, Paul, Widemann, Brigitte, Glod, John

Volltext

P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models von McGrath, L., Rosfjord, E., Christ, S., Zheng, Y., Floch, N., Sachs, C.C., Cotoi, C., Batelli, S., Cantu, E., Makaretz, S., Grenga, I., Arnaldez, F., Comer, F.

Volltext

P2.04-03 EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours von Aggarwal, C., Solomon, B., Spira, A., Massarelli, E., Lau, S.C.m., Le, X., Rolfo, C., Planchard, D., Felip, E., Wu, Y.-L., Ahn, M.-J., Goto, K., Azaro, A., Lissa, D., Hamid, O., McGrath, L., Maudsley, R., Hayward, C., Mathewson, A., Arnaldez, F., Grenga, I., Azzoli, C.

Volltext